满意度保证——生物制剂的“按效果付费”。 - Suppr

Suppr

超能文献

Satisfaction guaranteed--"payment by results" for biologic agents.

作者信息

Garber Alan M, McClellan Mark B

机构信息

Center for Health Care Evaluation at the Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.

出版信息

N Engl J Med. 2007 Oct 18;357(16):1575-7. doi: 10.1056/NEJMp078204.

DOI:10.1056/NEJMp078204

PMID:17942870

Abstract

摘要

相似文献

Satisfaction guaranteed--"payment by results" for biologic agents.

N Engl J Med. 2007 Oct 18;357(16):1575-7. doi: 10.1056/NEJMp078204.

Drug pricing: No cure, no cost.

BMJ. 2007 Jul 21;335(7611):122-3. doi: 10.1136/bmj.39267.432153.94.

Risk sharing and payment by results.

Clin Pharmacol Ther. 2008 May;83(5):666-7. doi: 10.1038/clpt.2008.15.

Bortezomib.

Nat Rev Drug Discov. 2003 Aug;2(8):611-2. doi: 10.1038/nrd1159.

Drugs "refund" scheme proposed for England and Wales.

BMJ. 2007 Jun 9;334(7605):1181. doi: 10.1136/bmj.39238.353657.DB.

NICE proposes faster process to appraise cheaper drugs.

BMJ. 2016 Oct 17;355:i5592. doi: 10.1136/bmj.i5592.

Bortezomib in multiple myeloma.

N Engl J Med. 2005 Sep 22;353(12):1297-8; author reply 1297-8. doi: 10.1056/NEJMc051943.

3 New Biologics To Be Worth $14B in Sales by 2019.

Manag Care. 2015 May;24(5):36-7.

[Inappropriate commercial presentation of selected drugs and associated overcost].

Farm Hosp. 2006 May-Jun;30(3):195-6. doi: 10.1016/s1130-6343(06)73972-1.

Implementation of the biosimilar pathway: economic and policy issues.

Seton Hall Law Rev. 2011;41(2):511-57.

引用本文的文献

Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma.

JAMA Netw Open. 2021 Jan 4;4(1):e2033761. doi: 10.1001/jamanetworkopen.2020.33761.

Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies.

Front Pharmacol. 2020 Dec 8;11:594446. doi: 10.3389/fphar.2020.594446. eCollection 2020.

Innovation in Oncology Drug Development.

J Oncol. 2019 Nov 23;2019:9683016. doi: 10.1155/2019/9683016. eCollection 2019.

Performance-Based Risk-Sharing Arrangements: U.S. Payer Experience.

J Manag Care Spec Pharm. 2017 Oct;23(10):1042-1052. doi: 10.18553/jmcp.2017.23.10.1042.

Sustainable Financing of Innovative Therapies: A Review of Approaches.

Pharmacoeconomics. 2016 Oct;34(10):971-80. doi: 10.1007/s40273-016-0416-x.

Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.

J Clin Oncol. 2015 Nov 10;33(32):3727-32. doi: 10.1200/JCO.2015.61.9569. Epub 2015 Aug 24.

The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.

Pharmacoeconomics. 2011 Apr;29(4):269-85. doi: 10.2165/11585930-000000000-00000.

Using comparative effectiveness research to inform policy and practice in the UK HHS: past, present and future.

Pharmacoeconomics. 2010;28(10):799-811. doi: 10.2165/11535260-000000000-00000.

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

BMC Health Serv Res. 2010 Jun 7;10:153. doi: 10.1186/1472-6963-10-153.

Access with evidence development in the UK: past experience, current initiatives and future potential.

Pharmacoeconomics. 2010;28(2):163-70. doi: 10.2165/11531410-000000000-00000.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Satisfaction guaranteed--"payment by results" for biologic agents.

N Engl J Med. 2007 Oct 18;357(16):1575-7. doi: 10.1056/NEJMp078204.

Drug pricing: No cure, no cost.

BMJ. 2007 Jul 21;335(7611):122-3. doi: 10.1136/bmj.39267.432153.94.

Risk sharing and payment by results.

Clin Pharmacol Ther. 2008 May;83(5):666-7. doi: 10.1038/clpt.2008.15.

Bortezomib.

Nat Rev Drug Discov. 2003 Aug;2(8):611-2. doi: 10.1038/nrd1159.

Drugs "refund" scheme proposed for England and Wales.

BMJ. 2007 Jun 9;334(7605):1181. doi: 10.1136/bmj.39238.353657.DB.

NICE proposes faster process to appraise cheaper drugs.

BMJ. 2016 Oct 17;355:i5592. doi: 10.1136/bmj.i5592.

Bortezomib in multiple myeloma.

N Engl J Med. 2005 Sep 22;353(12):1297-8; author reply 1297-8. doi: 10.1056/NEJMc051943.

3 New Biologics To Be Worth $14B in Sales by 2019.

Manag Care. 2015 May;24(5):36-7.

[Inappropriate commercial presentation of selected drugs and associated overcost].

Farm Hosp. 2006 May-Jun;30(3):195-6. doi: 10.1016/s1130-6343(06)73972-1.

Implementation of the biosimilar pathway: economic and policy issues.

Seton Hall Law Rev. 2011;41(2):511-57.

引用本文的文献

Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma.

JAMA Netw Open. 2021 Jan 4;4(1):e2033761. doi: 10.1001/jamanetworkopen.2020.33761.

Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies.

Front Pharmacol. 2020 Dec 8;11:594446. doi: 10.3389/fphar.2020.594446. eCollection 2020.

Innovation in Oncology Drug Development.

J Oncol. 2019 Nov 23;2019:9683016. doi: 10.1155/2019/9683016. eCollection 2019.

Performance-Based Risk-Sharing Arrangements: U.S. Payer Experience.

J Manag Care Spec Pharm. 2017 Oct;23(10):1042-1052. doi: 10.18553/jmcp.2017.23.10.1042.

Sustainable Financing of Innovative Therapies: A Review of Approaches.

Pharmacoeconomics. 2016 Oct;34(10):971-80. doi: 10.1007/s40273-016-0416-x.

Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.

J Clin Oncol. 2015 Nov 10;33(32):3727-32. doi: 10.1200/JCO.2015.61.9569. Epub 2015 Aug 24.

The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.

Pharmacoeconomics. 2011 Apr;29(4):269-85. doi: 10.2165/11585930-000000000-00000.

Using comparative effectiveness research to inform policy and practice in the UK HHS: past, present and future.

Pharmacoeconomics. 2010;28(10):799-811. doi: 10.2165/11535260-000000000-00000.

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

BMC Health Serv Res. 2010 Jun 7;10:153. doi: 10.1186/1472-6963-10-153.

Access with evidence development in the UK: past experience, current initiatives and future potential.

Pharmacoeconomics. 2010;28(2):163-70. doi: 10.2165/11531410-000000000-00000.